Last reviewed · How we verify
LXI-15028
LXI-15028 is a small molecule drug that targets the SGLT2 receptor.
LXI-15028 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | LXI-15028 |
|---|---|
| Sponsor | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
SGLT2 inhibitors like LXI-15028 work by blocking the reabsorption of glucose in the kidneys, thereby reducing blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes. LXI-15028's SGLT2 inhibition leads to increased glucose excretion in the urine, which helps to lower blood glucose levels.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
- Hypotension
Key clinical trials
- Mass Balance and Biotransformation Study of [14C]LXI-15028 in Humans (PHASE1)
- Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer (PHASE3)
- Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis (PHASE3)
- A Multi-center, Randomized, Double-blind, Parallel-group, Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of LXI-15028 in Non-erosive Reflux Disease in Chinese Patients for 4 Weeks (PHASE3)
- A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |